Rosiglitazone Metabolism in Human Liver Microsomes Using a Substrate Depletion Method

Area of Science:

• Pharmacology
• Drug Metabolism
• Biochemistry

Background:

• Hepatic metabolism is the primary route for rosiglitazone elimination in humans.
• Previous studies identified CYP2C8 as the major enzyme, with minor CYP2C9 involvement, but a comprehensive understanding of rosiglitazone metabolism remains incomplete.
• Potential involvement of additional cytochrome P450 enzymes and metabolic pathways necessitates further investigation.

Purpose of the Study:

• To elucidate the complete metabolic profile of rosiglitazone.
• To evaluate the kinetics of rosiglitazone metabolism.
• To assess the impact of specific enzyme inhibitors on rosiglitazone metabolism to predict potential drug-drug interactions.

Main Methods:

• In vitro oxidative metabolism of rosiglitazone was studied using human liver microsomes from five donors.
• The substrate concentration ranged from 0.5 to 500 µM.
• The contribution of CYP2C8, CYP2C9, CYP3A4, CYP2E1, and CYP2D6 to rosiglitazone metabolism was assessed using specific inhibitors.

Main Results:

• Rosiglitazone metabolism was significantly inhibited by inhibitors of CYP2C8 (69%), CYP2C9 (42%), CYP3A4 (52%), and CYP2E1 (41%).
• The maximum reaction velocity for rosiglitazone metabolism was determined to be 1.64 ± 0.98 nmol·mg⁻¹·min⁻¹.
• These findings indicate a substantial role for multiple CYP enzymes in rosiglitazone metabolism.

Conclusions:

• Cytochrome P450 enzymes CYP2C9, CYP3A4, and CYP2E1, in addition to CYP2C8, play significant roles in rosiglitazone metabolism.
• A comprehensive understanding of a drug's metabolic pathways is crucial for evaluating potential drug-drug interactions.
• This knowledge aids in refining therapeutic strategies and improving patient safety.